ctDNA detection using patient-specific panels in plasma samples collected at different points of NAT and preceding surgery from patients with high risk early breast cancer indicated that ctDNA detection following NAT was associated with worse outcomes13. The gene discussed is BRD2; the disease is breast cancer.